Video Center


The OBR Video Center Features educational videos covering a wide range of oncology specific topics.

Lalan Wilfong, MD, explains how OCM has impacted cancer patients in his practice

Dr. Wilfong, Director of Quality Programs for Texas Oncology; Physician Champion for OCM at McKesson Specialty Health, shares how OCM is affecting the cancer patients in his practice

Tags: COA Conference CoverageOncology Care Model (OCM)Policy and Value (includes Cost, Quality, Reimbursement, Guidelines, Pathways, Insurance)

Published: 04 May 2017

Recent Videos

video

Noa Biran, MD, considers the role of BCMA CAR-T cells in the management of multiple myeloma

Dr. Biran, Oncology Specialist, Division of Multiple Myeloma, John Theurer Cancer Center, Part of Hackensack University Medical Center, considers the ...

video

Frederick Locke, MD, offers opinion regarding off-the-shelf CAR-T cell therapies

Dr. Locke, Program Co-Leader, Immunology, Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and ...

video

Noa Biran, MD, provides her impression of the Phase 3 ICARIA-MM study

Dr. Biran, Oncology Specialist, Division of Multiple Myeloma, John Theurer Cancer Center, Part of Hackensack University Medical Center, provides her ...

video

Timothy Illidge, MD, PhD, describes the ECHELON-2 data presented at ASH 2019

Dr. Illidge, Professor of Targeted Therapy and Oncology, Division of Cancer Sciences, The Christie Hospital, University of Manchester, describes the ...

video

Noa Biran, MD, explains how JNJ-4528 differs from other CAR-T products

Dr. Biran, Oncology Specialist, Division of Multiple Myeloma, John Theurer Cancer Center, Part of Hackensack University Medical Center, explains how ...

video

Timothy Illidge, MD, PhD, explains the purpose of targeting peripheral t-cell lymphoma

Dr. Illidge, Professor of Targeted Therapy and Oncology, Division of Cancer Sciences, The Christie Hospital, University of Manchester, explains the ...

video

Noa Biran, MD, tells us about the outcomes of the CARTITUDE-1 study

Dr. Biran, Oncology Specialist, Division of Multiple Myeloma, John Theurer Cancer Center, Part of Hackensack University Medical Center, tells us ...

video

Ryan Lynch, MD, on how physicians should be thinking about BTK inhibitors in the treatment of CLL

Dr. Lynch, Assistant Professor of Medicine, Hematology/Oncology, University of Washington, Seattle Cancer Care Alliance, offers opinion on how physicians should ...

video

Timothy Illidge, MD, PhD, shares the the primary and secondary endpoints of the ECHELON-2 study

Dr. Illidge, Professor of Targeted Therapy and Oncology, Division of Cancer Sciences, The Christie Hospital, University of Manchester, shares the ...

video

Ryan Lynch, MD, offers his impressions of the Transcend-NHL data presented at ASH 2019

Dr. Lynch, Assistant Professor of Medicine, Hematology/Oncology, University of Washington, Seattle Cancer Care Alliance, offers his impressions of the Transcend-NHL ...

Related Videos

video-image

Jae H. Park, MD, regarding combination vemurafenib and obinutuzumab in hairy cell leukemia patients

video-image

Noa Biran, MD, explains how JNJ-4528 differs from other CAR-T products

video-image

Jeffrey Sharman, MD, shares updates from the CLL14 study presented at ASH 2019

video-image

Ryan Lynch, MD, tells us about the four-year update on the outcomes of the MURANO study

video-image

Andre Goy, MD, regarding the ZUMA-2 study investigating anti-CD19 CAR-T cell therapy MCL

video-image

Timothy Illidge, MD, PhD, describes the ECHELON-2 data presented at ASH 2019

video-image

Daniel Pollyea, MD, provides opinion on current treatment strategies for elderly AML patients

video-image

Christopher Yasenchak, MD, on the most impressive data in the treatment of Hodgkin’s lymphoma

video-image

Jae H. Park, MD, on the factors associated with improved survival after CD19 CAR-T cell therapy

video-image

Noa Biran, MD, provides her impression of the Phase 3 ICARIA-MM study

video-image

Jeffrey Sharman, MD, explains how we should be thinking about BTK inhibitors in the treatment of CLL

video-image

Ryan Lynch, MD, considers the ideal patient profile for zanubrutinib in RR-MCL

video-image

Andre Goy, MD, discusses the three-year survival analysis of the ZUMA-1 study from ASH 2019

video-image

Frederick Locke, MD, offers opinion regarding off-the-shelf CAR-T cell therapies

video-image

Daniel Pollyea, MD, speculates on how oral HMAs will impact the landscape in myeloid malignancies

video-image

Ryan Lynch, MD, on whether MRD is a valid endpoint when measuring treatment efficacy in CLL

video-image

Jae H. Park, MD, on incorporating CAR-T cell therapies into acute leukemia treatment algorithms

video-image

Noa Biran, MD, considers the role of BCMA CAR-T cells in the management of multiple myeloma

video-image

Jeffrey Sharman, MD, on the benefits of zanubrutinib as compared to other BTK inhibitors

video-image

Timothy Illidge, MD, PhD, on the impact of the ECHELON-2 trial data